Global Information
회사소개 | 문의 | 비교리스트

헌팅턴병 : 시장 기회, 역학적 예측, 영향요인, 파이프라인 분석(2020년 상반기)

Huntington´s Disease - Opportunity Assessments, Epidemiological Forecast Market Dynamics and Pipeline Analytics H1 2020

리서치사 GervanoRA Data Services LLP
발행일 2020년 07월 상품 코드 945743
페이지 정보 영문 185 Pages
가격
US $ 1,250 ₩ 1,476,000 PDF (Single User License)
US $ 1,800 ₩ 2,126,000 PDF (Site License)
US $ 2,500 ₩ 2,953,000 PDF (Global License)


헌팅턴병 : 시장 기회, 역학적 예측, 영향요인, 파이프라인 분석(2020년 상반기) Huntington´s Disease - Opportunity Assessments, Epidemiological Forecast Market Dynamics and Pipeline Analytics H1 2020
발행일 : 2020년 07월 페이지 정보 : 영문 185 Pages

헌팅턴병은 상염색체 우성 유전성 신경변성질환으로, 일반인구의 7,500명당 1명이 이환하고 있는 것으로 추정되고 있습니다.

세계의 헌팅턴병 치료제 시장을 조사했으며, 질환의 개요, 치료 알고리즘·가이드라인, 이환 상황, 파이프라인 동향, 미충족 요구와 시장 기회, 주요 파이프라인약, 개발의 마일스톤, 승인 전망, 현재·향후 경쟁 구도, 주요 기업의 개요 등을 정리하여 전해드립니다.

제1장 서론

제2장 개요

제3장 질환의 개요

  • 질환의 정의·증상
  • 질환의 원인·병태생리학
  • 질환 진단
  • 치료 알고리즘·가이드라인
  • 역학 연구
  • 역학 예측

제4장 헌팅턴병 치료제 : 시장 역학

  • 거래 : M&A·제휴
  • 특허 분석

제5장 파이프라인약 분석

  • 파이프라인 분석 : 단계별
    • 단계 3
    • 단계 2
    • 단계 1
    • 전임상
    • 초기 R&D
  • 파이프라인 분석 : 지역별
    • 미충족 요구·기회
  • 파이프라인 분석 : 투여 경로별
    • 미충족 요구·기회
  • 파이프라인 분석 : 약제 클래스별
    • 미충족 요구·기회
  • 파이프라인 분석 : 작용기서별
    • 미충족 요구·기회
  • 파이프라인 분석 : 분자 유형별
  • 파이프라인 분석 : 표적별
  • 파이프라인 분석 : 치료 유형별
  • 파이프라인 분석 : 기업 유형별

제6장 파이프라인약의 개요·개발 마일스톤

  • 단계 3
    • TOMINERSEN - CHUGAI PHARMACEUTICAL CO., LTD.
    • VALBENAZINE - NEUROCRINE BIOSCIENCES, INC
  • 단계 2
    • PEPINEMAB(VX15/2503) - VACCINEX INC
    • AMT-130 - UNIQURE NV
    • SOM3355 - SOM BIOTECH SL
    • WVE-120101 - WAVE LIFE SCIENCES AND TAKEDA
    • WVE-120102 - WAVE LIFE SCIENCES AND TAKEDA
    • SELISISTAT - AOP ORPHAN PHARMACEUTICALS AG
    • SRX246 - AZEVAN PHARMACEUTICALS INC
    • PRIDOPIDINE - PRILENIA THERAPEUTICS
    • CELLAVITA HD- AZIDUS
    • SBT-20 - STEALTH BIOTHERAPEUTICS CORP
    • TRIHEPTANOIN(UX007) - ULTRAGENYX PHARMACEUTICAL INC
    • LAQUINIMOD - ACTIVE BIOTECH AB
    • OMS824 - OMEROS CORP
  • 단계 1
    • CPL500036 INHIBITOR - CELON PHARMA SA
    • CKD-504- CHONG KUN DANG PHARMACEUTICAL CORP
    • ABC TRANSPORTERS- IMMUNGENETICS AG
    • MP101 - MITOCHON PHARMACEUTICALS INC
    • MMJ-002 AND MMJ-001 - MMJ INTERNATIONAL HOLDINGS CORP
    • SAGE-718 - SAGE THERAPEUTICS INC
    • NILOTINIB - NOVARTIS AG
    • T3D-959 - T3D THERAPEUTICS INC
    • MR-101 - SHINKEI THERAPEUTICS LLC
    • ORAL CANNABOSIDES - VITALITY BIOPHARMA INC

제7장 승인 추정 타임라인

제8장 경쟁 벤치마킹·시장 기회 평가

제9장 현재·향후 경쟁 구도

  • 신규 기업
KSA 20.07.15

LIST OF TABLES

  • TABLE 01: HUNTINGTON'S DISEASE REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: NUMBER OF CAG REPEATS AND OUTCOMES IN HUNTINGTON'S DISEASE
  • TABLE 03: HUNTINGTON'S DISEASE PREVALENCE, EUROPEAN COUNTRIES
  • TABLE 04: HUNTINGTON'S DISEASE PREVALENCE, AMERICA
  • TABLE 05: HUNTINGTON'S DISEASE PREVALENCE, ASIAN COUNTRIES
  • TABLE 06: COLLABORATION DEALS IN HUNTINGTON DISEASE THERAPEUTIC AREA
  • TABLE 07: FINANCING DEALS IN HUNTINGTON DISEASE THERAPEUTIC AREA
  • TABLE 08: LICENSING DEALS IN HUNTINGTON DISEASE THERAPEUTIC AREA
  • TABLE 09: MERGER AND ACQUISITION DEALS IN HUNTINGTON DISEASE THERAPEUTIC AREA
  • TABLE 10: HUNTINGTON'S DISEASE PIPELINE DRUGS BY STAGE OF DEVELOPMENT
  • TABLE 11: PHASE 3 PIPELINE MOLECULES FOR TREATING HUNTINGTON'S DISEASE
  • TABLE 12: PHASE 2 PIPELINE MOLECULES FOR TREATING HUNTINGTON'S DISEASE
  • TABLE 13: PHASE 1/2 PIPELINE MOLECULES FOR TREATING HUNTINGTON'S DISEASE
  • TABLE 14: PHASE 1 MOLECULES FOR TREATING HUNTINGTON'S DISEASE
  • TABLE 15: PRECLINICAL MOLECULES FOR TREATING HUNTINGTON'S DISEASE
  • TABLE 16: EARLY RESEARCH AND DEVELOPMENT MOLECULES FOR TREATING HUNTINGTON'S DISEASE
  • TABLE 17: CLINICAL STAGE DRUG CANDIDATES ALONG WITH SPECIAL REGULATORY ALLOWANCES
  • TABLE 18: PRECLINICAL STAGE DRUG CANDIDATES ALONG WITH SPECIAL REGULATORY ALLOWANCES
  • TABLE 19: HUNTINGTON'S DISEASE PIPELINE ANALYTICS BY INJECTABLE AS ROA
  • TABLE 20: HUNTINGTON'S DISEASE PIPELINE ANALYTICS BY ORAL AS ROA
  • TABLE 21: LIST OF PIPELINE MOLECULES WITH THEIR MECHANISM OF ACTIONS
  • TABLE 22: LIST OF PIPELINE MOLECULES WITH THEIR MOLECULAR TARGETS
  • TABLE 23: HUNTINGTON'S DISEASE PIPELINE DRUGS, TREATMENT TYPE
  • TABLE 24: HUNTINGTON'S DISEASE PIPELINE DRUGS ANALYTICS BY COMPANY TYPE
  • TABLE 25: REGION WISE STATISTICS, COMPANY COUNT WITH COUNT OF HUNTINGTON'S DISEASE PIPELINE CANDIDATES
  • TABLE 26: MILESTONES OF TOMINERSEN
  • TABLE 27: EXPLORATORY CLINICAL OUTCOME RESULTS OF TOMINERSEN
  • TABLE 28: MILESTONES OF VALBENAZINE
  • TABLE 29: MILESTONES OF PEPINEMAB (VX15/2503)
  • TABLE 30: MILESTONES OF AMT-130
  • TABLE 31: MILESTONES OF SOM3355
  • TABLE 32: MILESTONES OF WVE-120101
  • TABLE 33: MILESTONES OF WVE-120102
  • TABLE 34: MILESTONES OF SELISISTAT
  • TABLE 35: MILESTONES OF PRIDOPIDINE
  • TABLE 36: MILESTONES OF LAQUINIMOD
  • TABLE 37: MILESTONES OF OMS824
  • TABLE 38: MILESTONES OF CPL500036
  • TABLE 39: MILESTONES OF MP-101
  • TABLE 40: MILESTONES OF MMJ-002 AND MMJ-001
  • TABLE 41: MILESTONES OF SAGE-718
  • TABLE 42: GERVANORA ESTIMATED APPROVAL TIMELINES V/S ACTUAL APPROVAL DATE
  • TABLE 43: ESTIMATED APPROVAL TIMELINES OF HUNTINGTON'S DISEASE DRUG CANDDIATES (PHASE 3 AND PHASE 2)
  • TABLE 44: RANKING OF TOP EMERGING COMPANIES BASED ON REGULATORY ALLOWANCES
  • TABLE 45: PRIDOPIDINE STUDIES OF PRILENIA THERAPEUTICS
  • TABLE 46: PATENTS FILED IN THE U.S BY PRILENIA THERAPEUTICS
  • TABLE 47: PATENT APPLICATIONS FILED IN THE U.S BY PRILENIA THERAPEUTICS
  • TABLE 48: PATENT APPLICATIONS FILED IN OTHER THAN THE U.S BY PRILENIA THERAPEUTICS
  • TABLE 49: PUBLICATIONS OF PRILENIA THERAPEUTICS
  • TABLE 50: PIPELINE ASSETS OF AZEVAN
  • TABLE 51: PATENTS FILED IN THE U.S BY AZEVAN
  • TABLE 52: PATENT APPLICATIONS FILED IN THE U.S BY AZEVAN
  • TABLE 53: PATENT APPLICATIONS FILED OTHER THAN THE U.S BY AZEVAN
  • TABLE 54: PIPELINE ASSETS OF VACCINEX
  • TABLE 55: RESEARCH AND DEVELOPMENT ACTIVITIES VACCINEX
  • TABLE 56: RECENT DEVELOPMENTS OF VACCINEX
  • TABLE 57: PRESENTATION AND EVENTS OF VACCINEX
  • TABLE 58: PIPELINE ASSETS OF ACTIVE BIOTECH
  • TABLE 59: PATENTS OF ACTIVE BIOTECH
  • TABLE 60: RESEARCH AND DEVELOPMENT ACTITIVIES AND RECENT DEVELOPMENTS OF ACTIVE BIOTECH
  • TABLE 61: PRESENTATIONS AND EVENTS OF ACTIVE BIOTECH
  • TABLE 62: PUBLICATIONS OF ACTIVE BIOTECH
  • TABLE 63: PIPELINE ASSETS OF ORYZON
  • TABLE 64: PATENTS FILED IN THE U.S BY ORYZON
  • TABLE 65: PATENT APPLICATIONS FILED IN THE U.S BY ORYZON
  • TABLE 66: PATENT APPLICATIONS FILED OTHER THAN THE U.S BY ORYZON
  • TABLE 67: RESEARCH AND DEVELOPMENT ACTIVITIES OF ORYZON
  • TABLE 68: RECENT DEVELOPMENTS OF ORYZON
  • TABLE 69: PRESENTATION AND EVENTS OF ORYZON
  • TABLE 70: PIPELINE ASSETS OF SOM BIOTECH
  • TABLE 71: RESEARCH AND DEVELOPMENT ACTIVITIES OF SOM BIOTECH
  • TABLE 72: RECENT DEVELOPMENTS OF SOM BIOTECH
  • TABLE 73: PRESENTATIONS AND EVENTS OF SOM BIOTECH
  • TABLE 74: PIPELINE ASSETS OF WAVE LIFE SCIENCES UNDER CNS TREATMENTS
  • TABLE 75: PIPELINE ASSETS OF WAVE LIFE SCIENCES NON-CNS TREATMENT
  • TABLE 76: RESEARCH AND DEVELOPMENT ACTIVITIES OF WAVE LIFE SCIENCES
  • TABLE 77: RECENT DEVELOPMENTS OF WAVE LIFE SCIENCES
  • TABLE 78: PRESENTATION AND EVENTS OF WAVE LIFE SCIENCES
  • TABLE 79: PIPELINE ASSETS OF GENERVON
  • TABLE 80: PATENTS FILED IN THE U.S BY GENERVON
  • TABLE 81: PATENT APPLICATIONS FILED IN THE U.S BY GENERVON
  • TABLE 82: PATENT APPLICATIONS FILED OTHER THAN THE U.S BY GENERVON
  • TABLE 83: RESEARCH AND DEVELOPMENT ACTIVITIES OF GENERVON
  • TABLE 84: RECENT DEVELOPMENTS OF GENERVON
  • TABLE 85: PRESENTATION AND EVENTS OF GENERVON
  • TABLE 86: PIPELINE ASSETS OF T3D THERAPEUTICS
  • TABLE 87: PATENT APPLICATIONS FILED BY T3D THERAPEUTICS
  • TABLE 88: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF T3D THERAPEUTICS
  • TABLE 89: PRESENTATION AND EVENTS OF T3D THERAPEUTICS
  • TABLE 90: PUBLICATIONS OF T3D THERAPEUTICS
  • TABLE 91: PIPELINE ASSETS OF STEALTH BIOTHERAPEUTICS
  • TABLE 92: PATENTS FILED IN THE U.S BY STEALTH BIOTHERAPEUTICS
  • TABLE 93: PATENT APPLICATIONS FILED IN THE U.S BY STEALTH BIOTHERAPEUTICS
  • TABLE 94: PATENT APPLICATIONS FILED OTHER THAN THE U.S BY STEALTH BIOTHERAPEUTICS
  • TABLE 95: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF STEALTH BIOTHERAPEUTICS
  • TABLE 96: PRESENTATION AND EVENTS OF STEALTH BIOTHERAPEUTICS
  • TABLE 97: PUBLICATIONS OF STEALTH BIOTHERAPEUTICS
  • TABLE 98: PIPELINE ASSETS OF UNIQURE
  • TABLE 99: RESEARCH AND DEVELOPMENT ACTIVITIES OF UNIQURE
  • TABLE 100: RECENT DEVELOPMENTS OF UNIQURE
  • TABLE 101: PRESENTATION AND EVENTS OF UNIQURE
  • TABLE 102: PIPELINE ASSETS OF ANNEXON
  • TABLE 103: PATENTS FILED IN THE U.S BY ANNEXON
  • TABLE 104: PATENT APPLICATIONS FILED IN THE U.S BY ANNEXON
  • TABLE 105: PATENT APPLICATIONS FILED OTHER THAN THE U.S BY ANNEXON
  • TABLE 106: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF ANNEXON
  • TABLE 107: PUBLICATIONS OF ANNEXON
  • TABLE 108: PIPELINE ASSETS OF NEUBASE
  • TABLE 109: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF NEUBASE
  • TABLE 110: PRESENTATION AND EVENTS OF NEUBASE
  • TABLE 111: PUBLICATIONS OF NEUBASE
  • TABLE 112: PIPELINE ASSETS OF VOYAGER
  • TABLE 113: RESEARCH AND DEVELOPMENT ACTIVITIES OF VOYAGER
  • TABLE 114: RECENT DEVELOPMENTS OF VOYAGER
  • TABLE 115: PRESENTATION AND EVENTS OF VOYAGER
  • TABLE 116: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF VITALITY BIOPHARMA
  • TABLE 117: PRESENTATION AND EVENTS OF VITALITY BIOPHARMA

LIST OF FIGURES

  • FIGURE 01: KEY EVENTS IN THE HUNTINGTON'S DISEASE COMPETITIVE SPACE
  • FIGURE 02: ORIGINAL AND MUTATED DNA SEQUENCE OF HTT GENE
  • FIGURE 03: HD EXPECTED POPULATION FOR YEAR 2019 & 2025 IN THE US
  • FIGURE 04: HUNTINGTON DISEASE DEAL ANALYTICS BY DEAL TYPE
  • FIGURE 05: HUNTINGTON DISEASE DEAL ANALYTICS BY ANNUAL FREQUENCY (TILL APRIL 2020)
  • FIGURE 06: ACTIVE PLAYERS IN THE HUNTINGTON'S DISEASE MARKET
  • FIGURE 07: PIPELINE MOLECULES - CLINICAL VS PRECLINICAL & EARLY R&D
  • FIGURE 08: TOTAL PIPELINE MOLECULES VS STAGE OF DEVELOPMENT
  • FIGURE 09: HD PIPELINE DRUGS ANTICIPATING US & EU MARKET APPROVALS, HSD SPLITUP
  • FIGURE 10: HUNTINGTON'S DISEASE DRUG PIPELINE SPLIT BY ROA
  • FIGURE 11: HSD WISE REPRESENTATION OF INJECTABLE DRUGS
  • FIGURE 12: HSD WISE REPRESENTATION OF ORAL DRUGS
  • FIGURE 13: UNMET NEEDS & CHALLENGES TO DRUG DELIVERY
  • FIGURE 14: VARIOUS DRUG CLASSES IN HD DRUG PIPELINE
  • FIGURE 15: HD DRUG PIPELINE SPLIT BY MOLECULE TYPE
  • FIGURE 16: HSD WISE SPLIT UP OF SMALL MOLECULE DRUGS
  • FIGURE 17: HSD WISE SPLIT UP OF BIOLOGIC DRUGS
  • FIGURE 18: HUNTINGTON'S DISEASE PIPELINE DRUGS ANALYTICS BY TREATMENT TYPE
  • FIGURE 19: HUNTINGTON'S DISEASE PIPELINE DRUGS ANALYTICS BY TREATMENT TYPE AND HSD
  • FIGURE 20: HUNTINGTON'S DISEASES COMPANIES SPLIT BY COMPANY TYPE
  • FIGURE 21: GEOGRAPHICAL CATEGORIZATION OF COMPANIES WORKING ON HUNTINGTON'S DISEASE
  • FIGURE 22: COUNT OF COMPANIES FOCUSED ON NDD THERAPIES
  • FIGURE 23: MILESTONE ANALYTICS OF TOMINERSEN
  • FIGURE 24: MILESTONE ANALYTICS OF AMT-130
  • FIGURE 25: MILESTONE ANALYTICS OF SELISISTAT
  • FIGURE 26: MILESTONE ANALYTICS OF PRIDOPIDINE
  • FIGURE 27: RESEARCH AND DEVELOPMENT EXPENSES OF TOP 3 COMPANIES IN $M
  • FIGURE 28: PIPELINE PORTFOLIO WITH (NUMBER OF MOLECULES)
  • FIGURE 29: EXPECTED MARKET ENTRY WITH RESPECT TO DRUG CANDIDATES TREATING HUNTINGTON DISEASE
  • FIGURE 30: TIME LINE OF PATENT EXPIRIES WITH RESPECT TO HUNTINGTON DISEASE TREATMENTS
  • FIGURE 31: RANKING TOP 10 EMERGING COMPANIES BASED ON THEIR PARTNERING ACTIVITIES
  • FIGURE 32: R&D EXPENSES INCURRED BY VACCINEX FOR THE FINANCIAL YEARS OF 2018 AND 2019 IN $K
  • FIGURE 33: R&D EXPENSES AND REVENUES INCURRED BY WAVE LIFE SCIENCES
  • FIGURE 34: R&D EXPENSES & REVENUES ATTAINED BY UNIQURE FOR FINANCIAL YEAR END OF 2017, 2018 & 2019
  • FIGURE 35: R&D EXPENSES & REVENUES INCURRED BY VOYAGER FOR FINANCIAL YEARS OF 2017, 2018 & 2019 IN $K
  • FIGURE 36: R&D EXPENSES & REVENUES BY VITALITY BIOPHARMA FOR FINANCIAL YEAR END OF 2018 & 2019

Huntington's disease (HD) is a relentless neurodegenerative disease that results in profound disability through a triad of motor, cognitive and neuropsychiatric symptoms with very few therapeutic options. It is an Autosomal dominant, neurodegenerative disease that affects an estimated 1 in 7,500 individuals in the general population, making it one of the most common inherited neurodegenerative diseases. Huntington Disease is a result of mutation in Huntingtin (HTT) gene. Mutated HTT gene generates DNA segment known as a CAG trinucleotide repeat. Adult-onset HD, the most common form of the disease, typically manifests around 40 years of age as a broad spectrum of motor, cognitive and psychiatric disorders. It is predominantly characterized by involuntary choreic movements, behavioral changes and cognitive impairment, which are often preceded by psychiatric symptoms. HTT-targeted therapies are promising therapeutic approaches for the treatment of HD. The therapeutic area has been witnessing continuous research for both symptomatic and disease modifying therapies.

The report "Huntington's disease (HD) Pipeline Drugs - Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analytics, 2020" provides a global therapeutic landscape covering all the molecules under development for the treatment of the disease.

Huntington's disease therapeutics pipeline consists of around 87 molecules under development by a total of 82 companies worldwide. For a comprehensive analysis, we have classified the pipeline into segments based on the molecules' Highest Stage of Development, Drug Class, Mechanism of Action, Route of Administration, Geography, Molecule Type, Molecule Target, Treatment Type and Company Type.

The report is built to provide strategically important competitor information, analytics, and insights to formulate effective counter research and development strategies. Report concentrated more on emerging companies with potentially strong product portfolio and recognized significant and varied types of therapeutics under development. And report clearly explains the opportunities of co-development, partnering and investments.

Report helps emerging companies to understand the strong competitor strategies through its key company profiles and SWOT analysis. Elaborated report information assist clients in understanding the current scenarios in drug development and help in develop and design pipeline based in-licensing and out-licensing strategies. Following segments helps clients to understand this report with more clarity.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Unmet needs and Opportunities
  • Market Dynamics with Coverage of Deals (Licensing, Partnering, Collaborations, Financing etc.)
  • Patent Analytics of Pipeline Molecules
  • Pipeline Analysis of all Drug Molecules and Estimated Pipeline Drug Approval Time lines of Late Clinical Stage (Phase 2 and Phase 3) Pipeline Drug Candidates
  • Clinical Stage Drug Candidates' Descriptions along with Development Milestones
  • Opportunity Assessments through Competitive Benchmarking
  • Evaluate Current and Future Competitive Landscape through Company Profiles
  • Emerging Company Profiles with Opportunity Assessments

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

CHAPTER 01: INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. ABOUT US: GERVANORA DATA SERVICES

CHAPTER 02: EXECUTIVE SUMMARY

  • 2.1. REPORT SUMMARY
  • 2.2. KEY EVENTS IN THE HUNTINGTON'S DISEASE COMPETITIVE SPACE
  • 2.3. REPORT MAJOR FINDINGS
    • 2.3.1. DRIVERS
    • 2.3.2. RESTRAINTS
    • 2.3.3. OPPORTUNITIES

CHAPTER 03: DISEASE OVERVIEW

  • 3.1. DISEASE DEFINITION AND SYMPTOMS
  • 3.2. DISEASE CAUSE AND PATHOPHYSIOLOGY
  • 3.3. DISEASE DIAGNOSIS
  • 3.4. TREATMENT ALGORITHM AND GUIDELINES
  • 3.5. EPIDEMIOLOGY STUDIES
    • 3.5.1. GLOBAL AND HISTORICAL TRENDS
  • 3.6. EPIDEMIOLOGY FORECAST
    • 3.6.1. FORECAST METHODOLOGY AND ASSUMPTIONS
    • 3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST

CHAPTER 04: MARKET DYNAMICS OF HUNTINGTON'S DISEASE THERAPIES

  • 4.1. DEALS (MERGERS/ ACQUISITIONS/ COLLABORATIONS)
    • 4.1.1 DEALS ANALYTICS BY DEAL TYPE
      • 4.1.1.1. COLLABORATION DEALS
      • 4.1.1.2. FINANCING DEALS
      • 4.1.1.3. LICENSING DEALS
      • 4.1.1.4. MERGER AND ACQUISITION DEALS
    • 4.1.2 DEALS ANALYTICS BY ANNUAL FREQUENCY
    • 4.1.3 DEALS ANALYTICS BY ACTIVE PLAYER
  • 4.2. PATENT ANALYSIS (EXPIRIES AND GENERICIZATION)
    • 4.2.1. PATENT ANALYTICS OF PIPELINE DRUGS

CHAPTER 05: PIPELINE DRUGS ANALYTICS OF HUNTINGTON'S DISEASE

  • 5.1. PIPELINE DRUGS ANALYTICS BY STAGE OF DEVELOPMENT
    • 5.1.1. PHASE 3 PIPELINE MOLECULES
    • 5.1.2. PHASE 2 PIPELINE MOLECULES
    • 5.1.3. PHASE 1 PIPELINE MOLECULES
    • 5.1.4. PRECLINICAL PIPELINE MOLECULES
    • 5.1.5. EARLY R&D PIPELINE MOLECULES
  • 5.2. PIPELINE DRUGS ANALYTICS BY GEOGRAPHY
    • 5.2.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.3. PIPELINE DRUGS ANALYTICS BY ROUTE OF ADMINISTRATION
    • 5.3.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.4. PIPELINE DRUGS ANALYTICS BY DRUG CLASS
    • 5.4.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.5. PIPELINE DRUGS ANALYTICS BY MECHANISM OF ACTION
    • 5.5.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.6. PIPELINE DRUGS ANALYTICS BY MOLECULE TYPE
  • 5.7. PIPELINE DRUGS ANALYTICS BY TARGET
  • 5.8. PIPELINE DRUGS ANALYTICS BY TREATMENT TYPE
  • 5.9. PIPELINE DRUGS ANALYTICS BY COMPANY TYPE

CHAPTER 06: PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

  • 6.1. PHASE 3 PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
    • 6.1.1. TOMINERSEN - CHUGAI PHARMACEUTICAL CO., LTD.
      • 6.1.1.1. TOMINERSEN- DESCRIPTION
      • 6.1.1.2. TOMINERSEN- DEVELOPMENT MILESTONES
      • 6.1.1.3. TOMINERSEN- ESTIMATED APPROVAL YEAR
    • 6.1.2. VALBENAZINE - NEUROCRINE BIOSCIENCES, INC
      • 6.1.2.1. VALBENAZINE - DESCRIPTION
      • 6.1.2.2. VALBENAZINE - DEVELOPMENT MILESTONES
      • 6.1.2.3. VALBENAZINE - ESTIMATED APPROVAL YEAR
  • 6.2. PHASE 2 PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
    • 6.2.1. PEPINEMAB (VX15/2503) - VACCINEX INC
      • 6.2.1.1. PEPINEMAB (VX15/2503) - DESCRIPTION
      • 6.2.1.2. PEPINEMAB (VX15/2503) - DEVELOPMENT MILESTONES
    • 6.2.2. AMT-130 - UNIQURE NV
      • 6.2.2.1. AMT-130 - DESCRIPTION
      • 6.2.2.2. AMT-130 - DEVELOPMENT MILESTONES
    • 6.2.3. SOM3355 - SOM BIOTECH SL
      • 6.2.3.1. SOM3355 - DESCRIPTION
      • 6.2.3.2. SOM3355 - DEVELOPMENT MILESTONES
    • 6.2.4. WVE-120101 - WAVE LIFE SCIENCES AND TAKEDA
      • 6.2.4.1. WVE-120101 - DESCRIPTION
      • 6.2.4.2. WVE-120101 - DEVELOPMENT MILESTONES
    • 6.2.5. WVE-120102 - WAVE LIFE SCIENCES AND TAKEDA
      • 6.2.5.1. WVE-120102 - DESCRIPTION
      • 6.2.5.2. WVE-120102 - DEVELOPMENT MILESTONES
    • 6.2.6. SELISISTAT - AOP ORPHAN PHARMACEUTICALS AG
      • 6.2.6.1. SELISISTAT - DESCRIPTION
      • 6.2.6.2. SELISISTAT - DEVELOPMENT MILESTONES
    • 6.2.7. SRX246 - AZEVAN PHARMACEUTICALS INC
      • 6.2.7.1. SRX246 - DESCRIPTION
      • 6.2.7.2. SRX246 - DEVELOPMENT MILESTONES
    • 6.2.8. PRIDOPIDINE - PRILENIA THERAPEUTICS
      • 6.2.8.1. PRIDOPIDINE - DESCRIPTION
      • 6.2.8.2. PRIDOPIDINE - DEVELOPMENT MILESTONES
    • 6.2.9. CELLAVITA HD- AZIDUS
      • 6.2.9.1. CELLAVITA HD - DESCRIPTION
      • 6.2.9.2. CELLAVITA HD - DEVELOPMENT MILESTONES
    • 6.2.10. SBT-20 - STEALTH BIOTHERAPEUTICS CORP
      • 6.2.10.1. SBT-20 - DESCRIPTION
      • 6.2.10.2. SBT-20 - DEVELOPMENT MILESTONES
    • 6.2.11. TRIHEPTANOIN (UX007) - ULTRAGENYX PHARMACEUTICAL INC
    • 6.2.12. LAQUINIMOD - ACTIVE BIOTECH AB
    • 6.2.13. OMS824 - OMEROS CORP
  • 6.3. PHASE 1 PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
    • 6.3.1. CPL500036 INHIBITOR - CELON PHARMA SA
    • 6.3.2. CKD-504- CHONG KUN DANG PHARMACEUTICAL CORP
    • 6.3.3. ABC TRANSPORTERS- IMMUNGENETICS AG
    • 6.3.4. MP101 - MITOCHON PHARMACEUTICALS INC
    • 6.3.5. MMJ-002 AND MMJ-001 - MMJ INTERNATIONAL HOLDINGS CORP
    • 6.3.6. SAGE-718 - SAGE THERAPEUTICS INC
    • 6.3.7. NILOTINIB - NOVARTIS AG
    • 6.3.8. T3D-959 - T3D THERAPEUTICS INC
    • 6.3.9. MR-101 - SHINKEI THERAPEUTICS LLC
    • 6.3.10. ORAL CANNABOSIDES - VITALITY BIOPHARMA INC

CHAPTER 07: ESTIMATED APPROVAL TIMELINES OF HUNTINGTON'S DISEASE PIPELINE DRUGS

  • 7.1. METHODOLOGY
  • 7.2. ESTIMATED APPROVAL TIMELINES US & EX-US

CHAPTER 08: OPPORTUNITY ASSESSMENTS THROUGH COMPETITIVE BENCH-MARKING

  • 8.1. EXTERNAL DEPENDENCIES
  • 8.2. PIPELINE PORTFOLIO
  • 8.3. EXPECTED MARKET ENTRIES
  • 8.4. PATENTS AND EXCLUSIVITY
  • 8.5. MARKETING DYNAMICS AND PARTNERING
  • 8.6. ACHIEVEMENTS OF SPECIAL REGULATORY ALLOWANCES
  • 8.7. COMPANY DEVELOPMENTS

CHAPTER 09: CURRENT AND FUTURE COMPETITIVE LANDSCAPE

  • 9.1. EMERGING COMPANIES
    • 9.1.1. EMERGING COMPANY PROFILES
      • 9.1.1.1. PRILENIA THERAPEUTICS
      • 9.1.1.2. AZEVAN PHARMACEUTICALS, INC.
      • 9.1.1.3. VACCINEX, INC.
      • 9.1.1.4. ACTIVE BIOTECH AB
      • 9.1.1.5. ORYZON GENOMICS SA
      • 9.1.1.6. SOM INNOVATION BIOTECH SL
      • 9.1.1.7. WAVE LIFE SCIENCES LTD.
      • 9.1.1.8. GENERVON
      • 9.1.1.9. T3D THERAPEUTICS, INC.
      • 9.1.1.10. STEALTH BIOTHERAPEUTICS INC.
      • 9.1.1.11. UNIQURE N.V.
      • 9.1.1.12. ANNEXON BIOSCIENCES INC.
      • 9.1.1.13. NEUBASE THERAPEUTICS, INC.
      • 9.1.1.14. VOYAGER THERAPEUTICS, INC.
      • 9.1.1.15. VITALITY BIOPHARMA, INC.
Back to Top
전화 문의
F A Q